Reinventing Aptamer Science: The Neomer Platform In 2022, NeoVentures Biotechnology revolutionized aptamer science by introducing reproducibility, paving the way for the next generation of aptamers. Using our neomer platform, we reduced the number of random nucleotides while preserving optimal structural diversity. This innovation addressed the… Read More »The Next Generation of Aptamers
Ludwig Mies van der Rohe, famously said of architecture that “Less is more”. This principle is based on the idea that removing superfluous elements enhances the clarity of the concept. It emphasizes functionality, clean aesthetics and simplicity. The German pavilion that he designed for the… Read More »Aptamer architecture: Less is more in truncations
The Enzyme-Linked Immunosorbent Assay (ELISA) was invented by Swedish scientists Eva Engvall and Peter Perlmann in 1971. This groundbreaking diagnostic method revolutionized medicine by using antibodies to detect the presence of specific hormones or viruses, providing results much faster than traditional methods. The Enzyme-Linked Immunosorbent… Read More »The Enzyme-Linked Oligonucleotide Assay. The aptamer ELISA.
Background: By translating information on protein abundance to information on DNA abundance High-Plex proteomics brings deeper analysis than transcriptomics on a protein level. Pioneers like Olink and Somalogic have been leaders in building a future based on protein abundance. There are, however, weaknesses in the… Read More »The Aptamarker Platform
Keys to solving problems with aptamers: Obtain good specific aptamers We think that the only way to reliably obtain aptamers that will be specific enough for commercial applications is to use our reinvented Neomer library approach. Aptamer quality should be based on scientifically stringent binding… Read More »The NeoVentures’ Business Strategy Part 2
CRO: contract research organization. A company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. At NeoVentures, we do not consider ourselves as a (CRO). We approach what we do more as co-entrepreneurs with you. Clients come to… Read More »The NeoVentures’ Business Strategy Part 1
In year three of the French revolution, a law was enacted to realize the rallying cry, “un roi, une loi, un poids, et une mesure” (One king, one law, one weight, and one measure) and this became the introduction of the metric system. The one… Read More »The Importance Of What Is Difficult To Measure: How NeoVentures’ Aptamarker Platform Is Setting New Standards in Protein Measurement
One story embedded in One Thousand and One Nights is the story of Aladdin. A poor boy, that one day outsmarts the evil sorcerer and get hold of the magic lamp. Inside the lamp lives the genie, who will grant him all his wishes. Now,… Read More »Why Antibodies Wish They Could be DNA
In the dynamic realm of molecular biology, the quest for enhancing diagnostic tools and therapeutic approaches is an ever-evolving journey. One significant breakthrough in this pursuit is the development of the Neomer library, an innovative platform that allows the utilization of identical sequences across various… Read More »Unleashing the Potential of Neomer Library: A Revolutionary Approach to Aptamer Characterization and Improvement
Molecular Space Construction: NeoVentures Biotechnology’s Aptamarker platform leverages Aptamarker analysis to construct a molecular space, where individuals cluster based on unique biomolecular profiles. This space captures diversity in responses to diseases and allows for the nuanced exploration of different pathophysiological processes leading to the same… Read More »Aptamarker Use Case: Navigating the Molecular Landscape: Aptamarkers as the Compass for Patient Stratification
English 
French 
Spanish